ES2283671T3 - Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico. - Google Patents

Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico. Download PDF

Info

Publication number: ES2283671T3
Authority: ES; Spain
Prior art keywords: snx; omega; mviia; administration; binding
Prior art date: 1995-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES03007342T

Other languages

English (en)

Spanish (es)

Inventor

Ramasharma Kristipati

Peter Isadore Adriaenssens

Stephen Scott Bowersox

Theresa Gadbois

Robert R Luther

Gary Arthur Amstutz

Mark Raymond Pettus

Kishochandra Gohil

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai R&D Management Co Ltd

Original Assignee

Eisai R&D Management Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-27

Filing date

1996-06-26

Publication date

2007-11-01

1995-06-27 Priority claimed from US08/496,847 external-priority patent/US5795864A/en

1996-03-08 Priority claimed from US08/613,400 external-priority patent/US6054429A/en

1996-06-26 Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd

2007-11-01 Application granted granted Critical

2007-11-01 Publication of ES2283671T3 publication Critical patent/ES2283671T3/es

2016-06-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

208000004296 neuralgia Diseases 0.000 title claims abstract description 47
208000021722 neuropathic pain Diseases 0.000 title claims abstract description 46
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 23
208000035475 disorder Diseases 0.000 title claims abstract description 22
239000000203 mixture Substances 0.000 title description 36
230000036592 analgesia Effects 0.000 title description 13
239000003814 drug Substances 0.000 claims abstract description 39
238000004519 manufacturing process Methods 0.000 claims abstract description 9
230000027455 binding Effects 0.000 claims description 75
108090000765 processed proteins & peptides Proteins 0.000 claims description 32
238000007913 intrathecal administration Methods 0.000 claims description 22
210000003405 ileum Anatomy 0.000 claims description 15
230000008602 contraction Effects 0.000 claims description 14
241000700199 Cavia porcellus Species 0.000 claims description 12
230000001537 neural effect Effects 0.000 claims description 10
238000001990 intravenous administration Methods 0.000 claims description 6
208000028389 Nerve injury Diseases 0.000 claims description 5
230000008764 nerve damage Effects 0.000 claims description 5
230000008061 calcium-channel-blocking effect Effects 0.000 claims description 4
102000004129 N-Type Calcium Channels Human genes 0.000 claims 3
108090000699 N-Type Calcium Channels Proteins 0.000 claims 3
230000002401 inhibitory effect Effects 0.000 abstract description 4
150000001875 compounds Chemical class 0.000 description 69
BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 63
101000594607 Conus magus Omega-conotoxin MVIIA Proteins 0.000 description 61
239000012528 membrane Substances 0.000 description 40
208000004454 Hyperalgesia Diseases 0.000 description 31
241000700159 Rattus Species 0.000 description 31
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
230000000694 effects Effects 0.000 description 31
208000002193 Pain Diseases 0.000 description 30
238000012360 testing method Methods 0.000 description 30
230000036407 pain Effects 0.000 description 28
210000003568 synaptosome Anatomy 0.000 description 26
210000005036 nerve Anatomy 0.000 description 25
229940079593 drug Drugs 0.000 description 24
238000009472 formulation Methods 0.000 description 22
238000000034 method Methods 0.000 description 22
241001465754 Metazoa Species 0.000 description 21
210000004556 brain Anatomy 0.000 description 21
239000000243 solution Substances 0.000 description 21
238000002360 preparation method Methods 0.000 description 20
206010053552 allodynia Diseases 0.000 description 19
235000001014 amino acid Nutrition 0.000 description 18
238000001802 infusion Methods 0.000 description 16
239000000872 buffer Substances 0.000 description 15
210000004027 cell Anatomy 0.000 description 15
239000011780 sodium chloride Substances 0.000 description 15
102000004196 processed proteins & peptides Human genes 0.000 description 14
230000004044 response Effects 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
150000001413 amino acids Chemical class 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 13
229940001447 lactate Drugs 0.000 description 13
210000000278 spinal cord Anatomy 0.000 description 13
208000024891 symptom Diseases 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
229930006000 Sucrose Natural products 0.000 description 12
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
230000002981 neuropathic effect Effects 0.000 description 12
239000005720 sucrose Substances 0.000 description 12
108090000312 Calcium Channels Proteins 0.000 description 11
102000003922 Calcium Channels Human genes 0.000 description 11
238000006073 displacement reaction Methods 0.000 description 11
101001122068 Conus tulipa Omega-conotoxin TVIA Proteins 0.000 description 10
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 10
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 10
-1 antisympathetic Substances 0.000 description 10
239000011575 calcium Substances 0.000 description 10
230000002860 competitive effect Effects 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
229960004452 methionine Drugs 0.000 description 10
208000033808 peripheral neuropathy Diseases 0.000 description 10
208000001294 Nociceptive Pain Diseases 0.000 description 9
229930182817 methionine Natural products 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
230000000202 analgesic effect Effects 0.000 description 8
229940098773 bovine serum albumin Drugs 0.000 description 8
229910052791 calcium Inorganic materials 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
206010029260 Neuroblastoma Diseases 0.000 description 7
201000001119 neuropathy Diseases 0.000 description 7
230000007823 neuropathy Effects 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
229940127291 Calcium channel antagonist Drugs 0.000 description 6
101000594611 Conus magus Omega-conotoxin MVIIB Proteins 0.000 description 6
208000035154 Hyperesthesia Diseases 0.000 description 6
125000003275 alpha amino acid group Chemical group 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
239000000480 calcium channel blocker Substances 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
208000014674 injury Diseases 0.000 description 6
230000002035 prolonged effect Effects 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
108091006146 Channels Proteins 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000000576 arachnoid Anatomy 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 5
210000004209 hair Anatomy 0.000 description 5
238000002483 medication Methods 0.000 description 5
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
230000003040 nociceptive effect Effects 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
230000002093 peripheral effect Effects 0.000 description 5
210000000578 peripheral nerve Anatomy 0.000 description 5
239000000725 suspension Substances 0.000 description 5
239000011534 wash buffer Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
208000027520 Somatoform disease Diseases 0.000 description 4
238000010171 animal model Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000009137 competitive binding Effects 0.000 description 4
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
239000011521 glass Substances 0.000 description 4
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
108010052968 leupeptin Proteins 0.000 description 4
239000002858 neurotransmitter agent Substances 0.000 description 4
230000009871 nonspecific binding Effects 0.000 description 4
208000027753 pain disease Diseases 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
229910052700 potassium Inorganic materials 0.000 description 4
230000036515 potency Effects 0.000 description 4
239000013049 sediment Substances 0.000 description 4
230000002269 spontaneous effect Effects 0.000 description 4
210000000225 synapse Anatomy 0.000 description 4
230000008733 trauma Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
208000010886 Peripheral nerve injury Diseases 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000016571 aggressive behavior Effects 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
239000012148 binding buffer Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
238000001914 filtration Methods 0.000 description 3
229960002591 hydroxyproline Drugs 0.000 description 3
230000009610 hypersensitivity Effects 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
229940005483 opioid analgesics Drugs 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
230000035699 permeability Effects 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000011591 potassium Substances 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
230000009159 somatosensory pathway Effects 0.000 description 3
229960002811 ziconotide Drugs 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
KMPMSMYHNJUNSV-BYPYZUCNSA-N (2s)-4-methylsulfanyl-2-(sulfooxyamino)butanoic acid Chemical class CSCC[C@@H](C(O)=O)NOS(O)(=O)=O KMPMSMYHNJUNSV-BYPYZUCNSA-N 0.000 description 2
FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000001387 Causalgia Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
241001269524 Dura Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229920002873 Polyethylenimine Polymers 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000003502 anti-nociceptive effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000012152 bradford reagent Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
229960005015 local anesthetics Drugs 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000002418 meninge Anatomy 0.000 description 2
230000003957 neurotransmitter release Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000003961 penetration enhancing agent Substances 0.000 description 2
229950000964 pepstatin Drugs 0.000 description 2
108010091212 pepstatin Proteins 0.000 description 2
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
230000008447 perception Effects 0.000 description 2
239000008191 permeabilizing agent Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
210000003446 pia mater Anatomy 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
230000001953 sensory effect Effects 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
241000894007 species Species 0.000 description 2
238000003860 storage Methods 0.000 description 2
210000002330 subarachnoid space Anatomy 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000003356 suture material Substances 0.000 description 2
YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
239000002699 waste material Substances 0.000 description 2
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
241000237970 Conus <genus> Species 0.000 description 1
101000594405 Conus geographus Omega-conotoxin GVIA Proteins 0.000 description 1
101000940112 Conus geographus Omega-conotoxins GVIIA/GVIIB Proteins 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
241000237858 Gastropoda Species 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
208000034693 Laceration Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010061296 Motor dysfunction Diseases 0.000 description 1
MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 description 1
PQNASZJZHFPQLE-UHFFFAOYSA-N N(6)-methyllysine Chemical compound CNCCCCC(N)C(O)=O PQNASZJZHFPQLE-UHFFFAOYSA-N 0.000 description 1
RYFOQDQDVYIEHN-ZETCQYMHSA-N N,N-Dimethyllysine Chemical compound CN(C)[C@H](C(O)=O)CCCCN RYFOQDQDVYIEHN-ZETCQYMHSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
108010041640 SNX 202 Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000002181 anti-sympathetic effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
229910001626 barium chloride Inorganic materials 0.000 description 1
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
239000010951 brass Substances 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
238000004422 calculation algorithm Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
CYKDLUMZOVATFT-UHFFFAOYSA-N ethenyl acetate;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=O)OC=C CYKDLUMZOVATFT-UHFFFAOYSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
238000010304 firing Methods 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
229920000578 graft copolymer Polymers 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000005351 kimble Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
230000007383 nerve stimulation Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000014511 neuron projection development Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
FDQZTPPHJRQRQQ-NZPQQUJLSA-N omega-conotoxin GVIA Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N4C[C@H](O)C[C@H]4C(=O)N1)=O)CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N2)=O)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 FDQZTPPHJRQRQQ-NZPQQUJLSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229940124583 pain medication Drugs 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
208000027232 peripheral nervous system disease Diseases 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
229920000166 polytrimethylene carbonate Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229960001404 quinidine Drugs 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
150000003385 sodium Chemical class 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000003238 somatosensory effect Effects 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
210000001032 spinal nerve Anatomy 0.000 description 1
210000000273 spinal nerve root Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003462 sulfoxides Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000012085 test solution Substances 0.000 description 1
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
229950010357 tetrodotoxin Drugs 0.000 description 1
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
210000001103 thalamus Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
239000002023 wood Substances 0.000 description 1
108091058550 ω-conotoxin Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Control Of El Displays (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

ES03007342T 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico. Expired - Lifetime ES2283671T3 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US496847		1995-06-27
US08/496,847 US5795864A (en)	1995-06-27	1995-06-27	Stable omega conopetide formulations
US613400P		1996-03-08
US08/613,400 US6054429A (en)	1996-03-08	1996-03-08	Epidural method of producing analgesia

Publications (1)

Publication Number	Publication Date
ES2283671T3 true ES2283671T3 (es)	2007-11-01

Family

ID=27052304

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES03007342T Expired - Lifetime ES2283671T3 (es)	1995-06-27	1996-06-26	Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico.
ES96923511T Expired - Lifetime ES2194998T3 (es)	1995-06-27	1996-06-26	Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES96923511T Expired - Lifetime ES2194998T3 (es)	1995-06-27	1996-06-26	Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.

Country Status (13)

Country	Link
EP (2)	EP1336409B1 (2)
JP (1)	JP2838073B2 (2)
AT (2)	ATE359086T1 (2)
AU (1)	AU695166B2 (2)
CA (1)	CA2224795C (2)
DE (3)	DE69627153T2 (2)
DK (2)	DK0835126T3 (2)
ES (2)	ES2283671T3 (2)
FR (1)	FR05C0027I2 (2)
LU (1)	LU91181I2 (2)
NL (1)	NL300201I2 (2)
PT (2)	PT1336409E (2)
WO (1)	WO1997001351A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5931809A (en)	1995-07-14	1999-08-03	Depotech Corporation	Epidural administration of therapeutic compounds with sustained rate of release
JP2002509080A (ja) *	1998-02-20	2002-03-26	シンジェンタリミテッド	グラモストラ・スパチュラタの毒から得られる鎮痛性ペプチドおよびその使用
AUPP627498A0 (en)	1998-10-02	1998-10-22	University Of Queensland, The	Novel peptides - i
EP2412719A1 (en)	2002-12-02	2012-02-01	Xenome Ltd	Chi-conotoxin peptides
WO2004050690A1 (en)	2002-12-02	2004-06-17	Xenome Ltd	NOVEL χ-CONOTOXIN PEPTIDES (-I)
SG168407A1 (en)	2003-01-28	2011-02-28	Ironwood Pharmaceuticals Inc	Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7268109B2 (en)	2003-10-02	2007-09-11	Elan Pharmaceuticals, Inc.	Method for reducing pain
GB0410215D0 (en) *	2004-05-07	2004-06-09	Lescroart Pol	Nerve damage
US8188048B2 (en)	2006-06-23	2012-05-29	Xenome Limited	Combination therapy
US8673856B2 (en) *	2006-11-04	2014-03-18	Anygen Co., Ltd.	Omega conotoxins
EP2527360B1 (en)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009135258A1 (en) *	2008-05-06	2009-11-12	Cnsbio Pty Ltd	Methods and compositions for the management of pain using omega-conotoxins
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2994066A1 (en)	2008-12-03	2010-06-10	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase c agonists and methods of use
WO2018129556A1 (en)	2017-01-09	2018-07-12	Ardelyx, Inc.	Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en)	2008-12-31	2018-03-30	Ardelyx, Inc.	MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
MX366293B (es)	2012-08-21	2019-07-04	Ardelyx Inc	Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en)	2012-08-21	2019-08-13	Ardelyx, Inc.	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
LT2983667T (lt)	2013-04-12	2019-07-10	Ardelyx, Inc.	Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
SI3004138T1 (sl)	2013-06-05	2024-07-31	Bausch Health Ireland Limited	Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
EA201991676A1 (ru)	2017-01-09	2020-01-30	Арделикс, Инк.	Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en)	2017-01-09	2018-07-12	Ardelyx, Inc.	Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3926287A1 (de) *	1989-08-09	1991-02-21	Bernhard Clasbrummel	Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) *	1989-11-22	1991-09-24	Neurex Corporation	Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) *	1991-11-12	1993-05-27	Neurex Corporation	Compositions for delayed treatment of ischemia-related neuronal damage
SG50624A1 (en) *	1991-12-30	1998-07-20	Neurex Corp	Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) *	1993-02-17	1994-09-06	Bristol Myers Squibb Co	デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

1996
- 1996-06-26 DE DE69627153T patent/DE69627153T2/de not_active Expired - Lifetime
- 1996-06-26 DK DK96923511T patent/DK0835126T3/da active
- 1996-06-26 AT AT03007342T patent/ATE359086T1/de active
- 1996-06-26 WO PCT/US1996/011041 patent/WO1997001351A1/en not_active Ceased
- 1996-06-26 DE DE69637021T patent/DE69637021T2/de not_active Expired - Lifetime
- 1996-06-26 ES ES03007342T patent/ES2283671T3/es not_active Expired - Lifetime
- 1996-06-26 AT AT96923511T patent/ATE235914T1/de active
- 1996-06-26 ES ES96923511T patent/ES2194998T3/es not_active Expired - Lifetime
- 1996-06-26 AU AU64002/96A patent/AU695166B2/en not_active Ceased
- 1996-06-26 DE DE1996627153 patent/DE122005000043I2/de active Active
- 1996-06-26 CA CA002224795A patent/CA2224795C/en not_active Expired - Fee Related
- 1996-06-26 EP EP03007342A patent/EP1336409B1/en not_active Expired - Lifetime
- 1996-06-26 PT PT03007342T patent/PT1336409E/pt unknown
- 1996-06-26 EP EP96923511A patent/EP0835126B1/en not_active Expired - Lifetime
- 1996-06-26 PT PT96923511T patent/PT835126E/pt unknown
- 1996-06-26 DK DK03007342T patent/DK1336409T3/da active
- 1996-06-27 JP JP8188120A patent/JP2838073B2/ja not_active Expired - Fee Related
2005
- 2005-06-23 FR FR05C0027C patent/FR05C0027I2/fr active Active
- 2005-07-06 LU LU91181C patent/LU91181I2/fr unknown
- 2005-07-13 NL NL300201C patent/NL300201I2/nl unknown

Also Published As

Publication number	Publication date
DE122005000043I2 (de)	2006-08-03
DK0835126T3 (da)	2003-07-14
JPH09104634A (ja)	1997-04-22
JP2838073B2 (ja)	1998-12-16
ES2194998T3 (es)	2003-12-01
AU6400296A (en)	1997-01-30
EP1336409B1 (en)	2007-04-11
LU91181I2 (fr)	2005-09-06
ATE235914T1 (de)	2003-04-15
ATE359086T1 (de)	2007-05-15
NL300201I1 (nl)	2005-09-01
EP1336409A1 (en)	2003-08-20
DE122005000043I1 (de)	2006-06-29
EP0835126A1 (en)	1998-04-15
DE69637021D1 (de)	2007-05-24
DE69637021T2 (de)	2008-01-10
PT835126E (pt)	2003-07-31
AU695166B2 (en)	1998-08-06
DE69627153T2 (de)	2003-12-04
FR05C0027I1 (2)	2005-08-12
FR05C0027I2 (2)	2006-12-29
WO1997001351A1 (en)	1997-01-16
HK1058146A1 (en)	2004-05-07
DK1336409T3 (da)	2007-08-13
PT1336409E (pt)	2007-06-29
CA2224795A1 (en)	1997-01-16
CA2224795C (en)	2001-04-03
NL300201I2 (nl)	2006-02-01
EP0835126B1 (en)	2003-04-02
DE69627153D1 (de)	2003-05-08

Publication	Publication Date	Title
ES2283671T3 (es)	2007-11-01	Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico.
US5795864A (en)	1998-08-18	Stable omega conopetide formulations
US6054429A (en)	2000-04-25	Epidural method of producing analgesia
AU648052B2 (en)	1994-04-14	Compositions for treating ischemia-related neuronal damage
JP6279626B2 (ja)	2018-02-14	エンドモルフィンのμオピオイド受容体アゴニスト類似体
US20040138204A1 (en)	2004-07-15	Compositions and methods for pain reduction
JP2004524340A (ja)	2004-08-12	非ニューロパシー炎症性疼痛を治療するための化合物のペプチドクラスの新規の使用
JP2014210784A (ja)	2014-11-13	痛みの処置方法および鎮痛化合物のスクリーニング方法
JPH10511077A (ja)	1998-10-27	Ｎ末端基で切断されたダイノルフィン類似体を用いた鎮痛方法
US5559095A (en)	1996-09-24	Delayed treatment method of reducing ischemia-related neuronal damage
KR101933543B1 (ko)	2018-12-28	말초 신경 손상을 치료하기 위한 뉴레귤린의 용도
ES2268885T3 (es)	2007-03-16	Peptidos de chi-conotoxina como inhibidores de transportadores neuronales de anima.
WO1993010145A1 (en)	1993-05-27	Compositions for delayed treatment of ischemia-related neuronal damage
ES2319427T3 (es)	2009-05-07	Aplicaciones terapeuticas del peptido c.
ES2306885T3 (es)	2008-11-16	Derivados de bifalina y sus aplicaciones analgesicas.
Dolu et al.	2016	The effects of bupivacaine combined with different adjuvants on block onset and duration and on ion channel expressions (SCN9A, TRPM) in sciatic nerve block in rats
HK1058146B (en)	2007-10-05	Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
ES2564825T3 (es)	2016-03-29	Uso de un análogo de bifalina como un agente farmacéutico analgésico
ES2980047T3 (es)	2024-09-27	Métodos para tratar el dolor neuropático
JP5861215B2 (ja)	2016-02-16	神経ペプチドを用いた神経因性疼痛軽減薬剤ならびに抗うつ薬剤
XIAO et al.	2001	Modulation of BmKAS-1 and BmKl-3-2 to sodium channel in rat dorsal root ganglion neurons
WO2000056761A1 (es)	2000-09-28	Peptidos capaces de bloquear la respuesta a sustancias quimicas o estimulos termicos o mediadores de la inflamacion de los nociceptores, y composiciones que los contienen
Wasserman et al.	1973	Action of ATP on the neural tissue-limb deplant of the salamander
HK1006810B (en)	1999-03-19	Compositions comprising omega conotoxin peptide derivatives and their use for treating ischemia-related neuronal damage